Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore. Excepteur sint lorem cupidatat.

You may like:

PSA+COVID-19: Conference Highlights From ACR Convergence 2020

Conference Highlights from ACR Convergence 2020

PSA+COVID-19: Conference Highlights From ACR Convergence 2020

This 30-minute on-demand broadcast focuses on highlights from the ACR Convergence 2020 conference. You will learn about new evidence regarding psoriatic arthritis (PsA) in the context of COVID-19, presented in a clinical discussion with the prominent rheumatology expert in this clinical area. This broadcast features the latest data synthesized to provide information most relevant to clinical practice. Topics include efficacy and safety of existing and novel targeted therapies for PsA and strategies for minimizing the risk of infections and adverse events for patients with PsA at the time of the COVID-19 pandemic. 

  • Dr. Mease, Director, Rheumatology Research, University of Washington School of Medicine

    Philip J. Mease, MD, MACR
    Rheumatology Research
    Swedish Medical Center/Providence St. Joseph Health
    Clinical Professor,
    University of Washington School of Medicine
    Seattle, Washington

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planners (Forefront Collaborative):
    • Christine Tebben and Marianna Shershneva, MD, PhD

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Faculty Presenter: Philip J. Mease, MD, MACR
    • Consultant: AbbVie, Amgen, Boehringer Ingelheim, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun Pharmaceuticals, UCB
    • Speakers Bureau: AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, UCB 
    • Contracted Research: AbbVie, Amgen, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun Pharmaceuticals, UCB
  • Faculty Presenter: Madelaine A. Feldman, MD, FACR
    • Advisory Board: Bristol Myers Squibb, Gilead, Lilly, Merck, Pfizer, Samsung

As a result of participation in this educational activity, participants should increase their ability to:

  • Summarize findings from recent clinical trials on biologic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA

  • Discuss

    Discuss latest evidence about targeted synthetic DMARDs for treatment of PsA

  • identify

    Consider the impact of the COVID-19 pandemic on PsA care


Unless otherwise specifically prohibited, you may temporarily download one copy of the materials for personal, noncommercial use only. You may not modify or copy the materials, use them for any commercial purpose or public display (commercial or noncommercial), remove any copyright or other proprietary notations, or transfer the materials to another person or online site.

Activity Information

Target Audience
The target audiences are rheumatologists and nurse practitioner (NP) and physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with PsA can benefit from participation in this education.

Accreditation Statement
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Forefront Collaborative designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Content Review
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of ACR, Forefront Collaborative and Lilly. 

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.  

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs. 

Approved ACR Education Partner
This activity is included in the ACR’s Education Partner program. Independent reporting and the viewpoints expressed are those of Forefront Collaborative and its affiliates and do not represent the ACR. 

This activity is provided by Forefront Collaborative.

Commercial Support
This activity was supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.